IP Library Granted Patent US 11,896,234
Granted Patent B2
US 11,896,234 · App. 16/964,424 · Granted Feb 13, 2024

Apparatus and method of using in situ solidifying complex coacervates for vascular occlusion

Inventors: Shawn Patrick Fojtik (Park City, UT); Russell Stewart (Salt Lake City, UT)
Assignee: Fluidx Medical Technology, LLC
A61B17/12109A61B17/12031A61B17/12136A61B17/12195A61L24/0015A61L24/0042A61L24/046A61L24/108C08F220/34C08F220/56C08L79/02A61B2017/00893A61B2017/1205A61L2300/254A61L2300/256A61L2300/41A61L2300/416A61L2430/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,896,234
App. No.
16/964,424
Granted
Feb 13, 2024
Kind
B2
Abstract

Described herein are the use of fluid complex coacervates that produce solid adhesives in situ to anchor medical devices such as catheters in a blood vessel. The anchored devices permit the targeted delivery of bioactive agents. The anchored devices can perform as an embolic agent by reducing or preventing blood flow in the vessel. Additionally, the embolic produced from the solid adhesive produced in situ can also include one or more bioactive agents that can be released in a controlled manner.

Claims (20)

1. A method for anchoring a catheter in a blood vessel of a subject, the method comprising (a) inserting into a blood vessel of a subject a catheter; and (b) injecting into the catheter an injectable composition, wherein the injectable composition comprises water and oppositely charged polyelectrolytes and counterions, wherein the concentration of the counterions in the injectable composition is greater than the concentration of ions in the blood vessel, whereupon introduction of the injectable composition into the blood vessel a solid or gel is produced in situ that seals the catheter to an inner wall of the vessel.

2. The method of claim 1 , wherein the catheter comprises a first catheter and a second catheter, wherein the second catheter is extended further into the vessel than the first catheter, wherein the injectable composition is injected into the first catheter, whereupon introduction of the injectable composition into the blood vessel a solid or gel is produced in situ that seals the second catheter to the inner wall of the vessel.

3. The method of claim 2 , wherein the first catheter and second catheter are a co-axial catheter.

4. The method of claim 2 , wherein the second catheter comprises an occlusion balloon catheter.

5. The method of claim 2 , wherein the first catheter and second catheter are sistered to one another.

6. The method of claim 5 , wherein the diameter of the first catheter is greater than the diameter of the second catheter.

7. The method of claim 6 , wherein a tip of the second catheter extends past a tip of the first catheter.

8. The method of claim 2 , wherein the solid or gel completely seals the vessel.

9. The method of claim 2 , wherein the first catheter is removed from the vessel.

10. The method of claim 2 , wherein the second catheter is removed producing a hole that is filled with additional injectable composition to produce an embolus.

11. The method of claim 1 , further comprising injecting a bioactive agent in the second catheter.

12. The method of claim 1 , wherein the catheter comprises a first lumen and a second lumen, and wherein the catheter comprises an outer first aperture from the first lumen, wherein the injectable composition is injected into the first lumen and exits the outer first aperture, whereupon introduction of the injectable composition into the blood vessel a solid or gel is produced in situ that seals the catheter to the inner wall of the vessel.

13. The method of claim 12 , wherein the gel or solid completely seals the vessel.

14. The method of claim 12 , wherein the catheter is removed producing a hole that is filled with additional injectable composition to produce an embolus.

15. The method of claim 12 , further comprising injecting a bioactive agent in the second lumen of the catheter.

16. The method of claim 1 , wherein the injectable composition further comprises one or more bioactive agents.

17. The method of claim 16 , wherein the bioactive agent comprises a nucleic acid, an antibiotic, a pain reliever, an anti-inflammatory agent, an immune modulator, a growth factor, an enzyme inhibitor, a hormone, a mediator, a messenger molecule, a cell signaling molecule, a receptor agonist, an oncolytic, a chemotherapy agent, a receptor antagonist, an antibody fragment, a monoclonal antibody, an anti-angiogenic agent, or any combination thereof.

18. The method of claim 1 , wherein the injectable composition further comprises a radiographic contrast agent or a fluoroscopic contrast agent.

19. The method of claim 1 , wherein the anchored catheter reduces or inhibits blood flow to a tumor, an aneurysm, a varicose vein, or a vascular malformation.

20. The method of claim 1 , wherein the subject has a tumor.

Assignments (4)
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT OF REEL 068532 / FRAME 0658 Recorded May 12, 2025
From: FLUIDX MEDICAL TECHNOLOGY, INC.
To: MERIT MEDICAL SYSTEMS, INC.
Reel/Frame 071267/0515 →
SECURITY INTEREST Recorded Sep 9, 2024
From: FLUIDX MEDICAL TECHNOLOGY, INC.
To: MERIT MEDICAL SYSTEMS, INC.
Reel/Frame 068532/0658 →
CHANGE OF NAME Recorded Oct 31, 2023
From: FLUIDX MEDICAL TECHNOLOGY, LLC
To: FLUIDX MEDICAL TECHNOLOGY, INC.
Reel/Frame 065414/0050 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2020
From: FOJTIK, SHAWN PATRICK; STEWART, RUSSELL
To: FLUIDX MEDICAL TECHNOLOGY, LLC
Reel/Frame 053440/0326 →
Continuity (2)
Provisional Application 62622195 · Jan 26, 2018
Related Publication 20210045748A1 · Feb 18, 2021